Gynecologic cancers (ovarian, uterine, and cervical cancer) are a highly active area of clinical research at Parexel. We know the devastating effect these diseases have on women’s health and are fully engaged in fighting women’s cancer.
One of our primary areas of focus is ovarian cancer, which represents an ongoing challenge due to its high rate of recurrence after initial surgery and chemotherapy. Our global studies on maintenance therapy following chemotherapy have significantly increased the amount of time before progression, utilizing a class of agents known as “PARP inhibitors.” These take advantage of a cancer cell’s inability to repair DNA defects, thus creating “synthetic lethality.”
Parexel’s Oncology Center of Excellence offers access to an optimal blend of subject matter experts in oncology and gynecologic cancers.
Our experienced gynecologic oncology project team will help optimize your protocol for clinical execution, and analyze data in real time, to enable your team to make informed decisions quickly.
Patients are at the center of all we do. We understand the high degree of sensitivity gynecologic cancer patients need, and that therapies don’t only affect them but also their family and loved ones.
As a proven gynecology cancer CRO, we leverage strong relationships with sites and advocacy groups to reach and retain highly specific patient cohorts around the world — even in competitive environments.
Experience in the past 5 years with gynecologic cancers
+
clinical projects
+
unique sites
+